Publication Date
5-1-2023
Journal
The Texas Heart Journal
DOI
10.14503/THIJ-22-7974
PMID
37268281
Publication Date(s)
May 2023
Language
English
PMCID
PMC10353275
PubMedCentral® Posted Date
5-26-2023
PubMedCentral® Full Text Version
Post-Print
Published Open-Access
yes
Keywords
Adolescent, Female, Humans, Atrial Fibrillation, Tachycardia, Ventricular, Anti-Arrhythmia Agents, Treatment Outcome, Defibrillators, Implantable
Copyright
This work is licensed under a Creative Commons Attribution-NonCommercial-No Derivative Works 4.0 International License.
Abstract
Catecholaminergic polymorphic ventricular tachycardia is a rare but lethal heritable arrhythmia syndrome associated with both atrial and ventricular arrhythmias. Treatment includes antiarrhythmics, sympathetic denervation, and implantable cardioverter-defibrillators. The use of atrioventricular nodal ablation as a treatment strategy to prevent ventricular arrhythmias in catecholaminergic polymorphic ventricular tachycardia was not found in the literature. This report describes a teenager with a presenting rhythm of atrial and ventricular fibrillation and cardiac arrest. Her clinical arrhythmia was predominantly atrial dysrhythmias, which delayed her diagnosis of catecholaminergic polymorphic ventricular tachycardia. Before her diagnosis, she underwent atrioventricular nodal ablation in an effort to prevent ventricular arrhythmias, which was ultimately ineffective. This report highlights the importance of recognizing atrial arrhythmias in catecholaminergic polymorphic ventricular tachycardia and provides evidence that atrioventricular nodal ablation is not an effective treatment strategy for this disease.